Virginia Albiñana - Search Results

Year	Number of Results
2008	1
2010	2
2011	1
2012	1
2013	1
2015	2
2016	1
2017	3
2019	3
2020	4
2021	3
2022	0

1

Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding.

Albiñana V, Cuesta AM, Rojas-P I, Gallardo-Vara E, Recio-Poveda L, Bernabéu C, Botella LM. Albiñana V, et al. J Clin Med. 2020 Jun 6;9(6):1766. doi: 10.3390/jcm9061766. J Clin Med. 2020. PMID: 32517280 Free PMC article. Review.

2

A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).

Zarrabeitia R, Albiñana V, Salcedo M, Señaris-Gonzalez B, Fernandez-Forcelledo JL, Botella LM. Zarrabeitia R, et al. Among authors: albinana v. Curr Vasc Pharmacol. 2010 Jul;8(4):473-81. doi: 10.2174/157016110791330771. Curr Vasc Pharmacol. 2010. PMID: 19485912 Review.

3

CLN5 in heterozygosis may protect against the development of tumors in a VHL patient.

de Rojas-P I, Albiñana V, Recio-Poveda L, Rodriguez-Rufián A, Cuesta ÁM, Botella LM. de Rojas-P I, et al. Among authors: albinana v. Orphanet J Rare Dis. 2020 Jun 2;15(1):132. doi: 10.1186/s13023-020-01410-y. Orphanet J Rare Dis. 2020. PMID: 32487141 Free PMC article.

4

The Endothelial Landscape and Its Role in Von Hippel-Lindau Disease.

de Rojas-P I, Albiñana V, Taranets L, Recio-Poveda L, Cuesta AM, Popov N, Kronenberger T, Botella LM. de Rojas-P I, et al. Among authors: albinana v. Cells. 2021 Sep 4;10(9):2313. doi: 10.3390/cells10092313. Cells. 2021. PMID: 34571962 Free PMC article.

5

Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds.

Marcos S, Botella LM, Albiñana V, Arbia A, de Rosales AM. Marcos S, et al. Among authors: albinana v. J Clin Med. 2021 Aug 27;10(17):3845. doi: 10.3390/jcm10173845. J Clin Med. 2021. PMID: 34501293 Free PMC article.

6

Differential Expression of Circulating Plasma miRNA-370 and miRNA-10a from Patients with Hereditary Hemorrhagic Telangiectasia.

Ruiz-Llorente L, Albiñana V, Botella LM, Bernabeu C. Ruiz-Llorente L, et al. Among authors: albinana v. J Clin Med. 2020 Sep 3;9(9):2855. doi: 10.3390/jcm9092855. J Clin Med. 2020. PMID: 32899377 Free PMC article.

7

Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.

Albiñana V, Gallardo-Vara E, de Rojas-P I, Recio-Poveda L, Aguado T, Canto-Cano A, Aguirre DT, Serra MM, González-Peramato P, Martínez-Piñeiro L, Cuesta AM, Botella LM. Albiñana V, et al. J Clin Med. 2020 Aug 25;9(9):2740. doi: 10.3390/jcm9092740. J Clin Med. 2020. PMID: 32854260 Free PMC article.

8

Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition).

Albiñana V, Giménez-Gallego G, García-Mato A, Palacios P, Recio-Poveda L, Cuesta AM, Patier JL, Botella LM. Albiñana V, et al. TH Open. 2019 Jul 26;3(3):e230-e243. doi: 10.1055/s-0039-1693710. eCollection 2019 Jul. TH Open. 2019. PMID: 31360828 Free PMC article.

9

Research on potential biomarkers in hereditary hemorrhagic telangiectasia.

Botella LM, Albiñana V, Ojeda-Fernandez L, Recio-Poveda L, Bernabéu C. Botella LM, et al. Among authors: albinana v. Front Genet. 2015 Mar 31;6:115. doi: 10.3389/fgene.2015.00115. eCollection 2015. Front Genet. 2015. PMID: 25873934 Free PMC article.

10

SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population.

Marcos S, Albiñana V, Recio-Poveda L, Tarazona B, Verde-González MP, Ojeda-Fernández L, Botella LM. Marcos S, et al. Among authors: albinana v. J Clin Med. 2021 Apr 27;10(9):1884. doi: 10.3390/jcm10091884. J Clin Med. 2021. PMID: 33925423 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results